WO2025215514 - SPLINT-MEDIATED RNA SYNTHESIS
National phase entry is expected:
Publication Number
WO/2025/215514
Publication Date
16.10.2025
International Application No.
PCT/IB2025/053671
International Filing Date
07.04.2025
Title **
[English]
SPLINT-MEDIATED RNA SYNTHESIS
[French]
SYNTHÈSE D'ARN MÉDIÉE PAR PONTS
Applicants **
CRISPR THERAPEUTICS AG
Inventors
WANG, Albert
ZHOU, Cong
GU, Tiancheng
Priority Data
63/631,331
08.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4260 | |
| EPO | Filing, Examination, Granting | 63119 | |
| Japan | Filing, Examination, Granting | 4131 | |
| South Korea | Filing, Examination, Granting | 5909 | |
| USA | Filing, Examination, Granting | 16940 |
Total:
94,359
Contact Us
Abstract[English]
The present disclosure relates to methods, compositions and kits for synthesizing long RNAs by splint-mediated ligation of RNA fragments using one or more DNA oligonucleotide. In some embodiments, the DNA oligonucleotide is no longer than 26 nucleotides. In some embodiments, the RNAs synthesized using the methods described herein can comprise a spacer sequence substantially complementary to a sequence in a target DNA, a scaffold sequence capable of binding to an RNA-guided endonuclease or a variant thereof, and an extended sequence region comprising one or more intended nucleotide edits compared to the sequence of the target DNA.[French]
La présente divulgation concerne des procédés, des compositions et des kits pour synthétiser des ARN longs par ligature médiée par ponts de fragments d'ARN à l'aide d'un ou de plusieurs oligonucléotides d'ADN. Dans certains modes de réalisation, l'oligonucléotide d'ADN ne contient pas plus de 26 nucléotides. Dans certains modes de réalisation, les ARN synthétisés à l'aide des procédés décrits ici peuvent comprendre une séquence d'espacement sensiblement complémentaire d'une séquence dans un ADN cible, une séquence d'échafaudage apte à se lier à une endonucléase guidée par ARN ou un variant de celle-ci, ainsi qu'une région de séquence étendue comprenant une ou plusieurs éditions nucléotidiques prévues par rapport à la séquence de l'ADN cible.